Population Pharmacokinetics of Piperaquine after Two Different Treatment Regimens with Dihydroartemisinin-Piperaquine in Patients with Plasmodium falciparum Malaria in Thailand
暂无分享,去创建一个
K. Stȩpniewska | K. Stepniewska | E. Ashley | N. Day | J. Tarning | M. Ashton | R. McGready | N. Day | F. Nosten | K. Stepniewska | N. White | J. Tarning | E. A. Ashley | N. Lindegardh | L. Phaiphun | N. P. J. Day | R. McGready | M. Ashton | F. Nosten | N. J. White | L. Phaiphun | N. Lindegårdh | N. White | F. Nosten
[1] F. Nosten,et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] N. Day,et al. Development and validation of an automated solid phase extraction and liquid chromatographic method for the determination of piperaquine in urine. , 2006, Journal of pharmaceutical and biomedical analysis.
[3] Mats O. Karlsson,et al. Assessment of Type I Error Rates for the Statistical Sub-model in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[4] R. Price,et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] J. Bergquist,et al. Characterization of Human Urinary Metabolites of the Antimalarial Piperaquine , 2006, Drug Metabolism and Disposition.
[6] S. Hewitt,et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. , 2002, Clinical Infectious Diseases.
[7] C. Dolecek,et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial , 2004, The Lancet.
[8] R. Price,et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison , 2007, The Lancet.
[9] T. Davis,et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. , 2003, British journal of clinical pharmacology.
[10] F. Nosten,et al. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. , 1999, The American journal of tropical medicine and hygiene.
[11] H. Webster,et al. The epidemiology of malaria in a Karen population on the western border of Thailand. , 1996, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[12] N. Day,et al. High throughput assay for the determination of piperaquine in plasma. , 2005, Journal of pharmaceutical and biomedical analysis.
[13] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.
[14] T. Davis,et al. Effects of a High-Fat Meal on the Relative Oral Bioavailability of Piperaquine , 2005, Antimicrobial Agents and Chemotherapy.
[15] N. White,et al. Delaying antimalarial drug resistance with combination chemotherapy. , 1999, Parassitologia.
[16] Mats O. Karlsson,et al. Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[17] Stuart L. Beal,et al. Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[18] R. Price,et al. Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria , 2007, Antimicrobial Agents and Chemotherapy.
[19] F. Nosten,et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. , 2004, The Journal of infectious diseases.
[20] M. Ashton,et al. Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects , 2006, European Journal of Clinical Pharmacology.
[21] L B Sheiner,et al. Estimating population kinetics. , 1982, Critical reviews in biomedical engineering.
[22] J. Barré,et al. Food increases the bioavailability of mefloquine , 1997, European Journal of Clinical Pharmacology.
[23] Amin Rostami-Hodjegan,et al. Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.
[24] N. Day,et al. Pitfalls in Estimating Piperaquine Elimination , 2005, Antimicrobial Agents and Chemotherapy.
[25] D. Hattis,et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[26] S. Hewitt,et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. , 2003, British journal of clinical pharmacology.
[27] B. Weatherley,et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. , 1994, British journal of clinical pharmacology.
[28] S. Krudsood,et al. An open randomized clinical trial of Artekin vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. , 2005, The Southeast Asian journal of tropical medicine and public health.
[29] Justin J. Wilkins,et al. NONMEMory: A run management tool for NONMEM , 2005, Comput. Methods Programs Biomed..
[30] A. Breckenridge,et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.